Breaking News

GSK says long-acting HIV prevention drug 66% more effective than Truvada

GSK says long-acting HIV prevention drug 66% more effective than TruvadaHIV incidence rate - or the number of people who contract the infection in a period - was 0.41% with the injection, compared with 1.22% with Gilead's Truvada, final data from a study presented at the virtual AIDS conference showed. Truvada is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit. "This advancement has the potential to be a game-changer for HIV prevention, offering ... the convenience of reduced dosing from daily to just six times per year," said Kimberly Smith, head of research and development at ViiV Healthcare.




from Yahoo News - Latest News & Headlines https://ift.tt/2ZK5Fzc
via IFTTT

No comments